These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19757314)

  • 1. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
    Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V; Arrigo C; Righi M
    Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract]   [Full Text] [Related]  

  • 4. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET
    Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
    Cheah CY; Seymour JF
    Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
    Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
    Liu CY; Teng HW; Lirng JF; Chiou TJ; Chen PM; Hsiao LT
    Leuk Lymphoma; 2008 Oct; 49(10):2018-21. PubMed ID: 18728965
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
    Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
    Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
    Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
    Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
    Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
    [No Abstract]   [Full Text] [Related]  

  • 13. Intra-CSF rituximab for lymhomatous meningitis.
    Chamberlain MC; Glantz MJ
    J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab for bone lymphoma.
    Savage DG; Staron R
    Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
    Crump M
    Leuk Lymphoma; 2006 Dec; 47(12):2437-9. PubMed ID: 17169786
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
    Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
    Ohguro N; Hashida N; Tano Y
    Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab for BCL-2-positive cancers.
    Boughton B
    Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.